Customer Contact Center:
1-888-PLMZYME (756-9963)

Indication Statement:

Daily administration of Pulmozyme (dornase alfa) in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.

Important Safety Information

  • Pulmozyme should not be used in patients with known hypersensitivity to dornase alfa, or any ingredients of the product.
  • Pulmozyme should be used in conjunction with standard therapies for CF.
  • Most common reported adverse events associated with the use of Pulmozyme include: voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis.

Pulmozyme Access Solutions®

Pulmozyme Access Solutions

Financial Support

Pulmozyme® Access Solutions® connects your patients to their medicine. We are committed to helping all patients access our medicines, regardless of their ability to pay.

Pulmozyme Access Solutions Logo

Our dedicated staff of specialists can:

  • Resolve benefits and coverage issues
  • Find co-pay assistance for uninsured patients
  • Help uninsured patients apply for free medicine through the Genentech® Access to Care Foundation
  • Individualize services to meet your patients' specific needs.

To learn more, visit www.PulmozymeAccessSolutions.com

Additional patient financial support resources include:

To speak live with an Access Solutions Specialist about these assistance resources, call 1-800-690-3023 from 6AM-5PM PT, Monday to Friday.

Fax: 1-800-963-1792
Web: www.PulmozymeAccessSolutions.com